ACRS
Aclaris Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$5.50
+1.85%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 147.01x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.50x
- Price / sales
- 98.50x
- Price / cash flow
- -13.05x
Enterprise value
- Enterprise value
- $718.0M
- EV / sales
- 87.36x
- EV / EBITDA
- -9.56x
- EV / EBIT
- -8.32x
- Market cap
- $809.6M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026